Recent

% | $
Quotes you view appear here for quick access.

Oncolytics Biotech Inc. Message Board

Title   Replies Latest Post

ONCY / ONCYf - Abbvie spends US $10.2 Billion to acquire Phase 1/2 cancer development comp...

Apr 28, 2016 6:57 PM by bailey201306
0/0 3 Apr 28, 2016 7:40 PM by bailey201306

ONCY / ONC.TO - Reovirus Plasticity for Improving Its Use as Oncolytic Virus

Apr 18, 2016 10:04 AM by bailey201306
0/0 0 Apr 18, 2016 10:04 AM by bailey201306

ONC.TO - Reolysin demonstrates statistical significance in 2 years survival data in Pancre...

Apr 14, 2016 10:11 AM by bailey201306
1/0 2 Apr 14, 2016 3:29 PM by oncdreamer

ONC.TO - Reovirus in Liver Metastases due to metastatic CRC

Apr 11, 2016 5:04 PM by bailey201306
0/0 0 Apr 11, 2016 5:04 PM by bailey201306

Thomson Reuters 12 month targets and a Buy Rating. 10:11am this morning

Apr 1, 2016 7:40 AM by oncdreamer
0/0 0 Apr 1, 2016 7:40 AM by oncdreamer

Boehringer Ingelheim invests in Cancer Vaccine development

Mar 31, 2016 11:01 AM by bailey201306
0/0 0 Mar 31, 2016 11:01 AM by bailey201306

Johns Hopkins Launches $125M Immunotherapy Institute

Mar 29, 2016 7:18 PM by bailey201306
0/0 0 Mar 29, 2016 7:18 PM by bailey201306

Time Magazine : March 24, 2016

Mar 26, 2016 6:20 PM by bailey201306
0/0 0 Mar 26, 2016 6:20 PM by bailey201306

ONCY / ONC.TO Phase 2 Ovarian Trial Mid Phase results show statistical significance & ...

Mar 24, 2016 11:30 AM by bailey201306
0/0 1 Mar 24, 2016 11:43 AM by bailey201306

Wow! The Stable disease and full response data is impressive.

Mar 22, 2016 3:47 PM by oncdreamer
0/1 0 Mar 22, 2016 3:47 PM by oncdreamer

Roche announces a Billion Deal with emerging/early stage biotech company in the cancer sp...

Mar 15, 2016 3:02 PM by bailey201306
0/0 1 Mar 15, 2016 3:10 PM by bailey201306

ONC.TO - I/O drug combinations with PD-1- ASCO GU 2016 Immune Checkpoint Blockers - Sessio...

Mar 14, 2016 8:02 PM by bailey201306
0/0 0 Mar 14, 2016 8:02 PM by bailey201306

ONCY / ONCYf / ONC.TO - Reolysin upregulates PD-1 - ultimately targeting trunck mutations ...

Mar 7, 2016 2:16 PM by bailey201306
0/0 2 Mar 14, 2016 5:37 PM by bailey201306

ONC.TO related : How oncolytic viruses are coming of age in cancer immunotherapy combinati...

Mar 1, 2016 7:35 PM by bailey201306
0/0 0 Mar 1, 2016 7:35 PM by bailey201306

The latest answers to cancer immunotherapy

Feb 13, 2016 12:29 PM by bailey201306
0/0 1 Mar 1, 2016 6:38 PM by bailey201306

2016 - Clinical Milestones in Cancer Immunotherapy - The Motely Fool Comments

Feb 27, 2016 3:20 PM by bailey201306
0/1 1 Feb 27, 2016 3:25 PM by bailey201306

Canaccord Genuity Group announces major layoffs

Feb 10, 2016 3:23 PM by bailey201306
0/0 0 Feb 10, 2016 3:23 PM by bailey201306

To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses

Feb 9, 2016 1:16 PM by bailey201306
0/0 0 Feb 9, 2016 1:16 PM by bailey201306

The Business of Immuno-Oncology

Feb 4, 2016 6:13 PM by bailey201306
0/1 0 Feb 4, 2016 6:13 PM by bailey201306

ONC.TO - Reovirus ready for clinical testing in CLL

Jan 21, 2016 6:32 PM by bailey201306
0/0 0 Jan 21, 2016 6:32 PM by bailey201306

Help Us Make it Better!

We are in the process of testing our new message boards.
Please provide your feedback so that we can optimize the user experience.

Go
Must Watch
ONC.TO
0.65+0.03(+4.84%)10:43 AMEDT